Nasdaq panel grants CNS Pharmaceuticals temporary exception until March 11, 2025 to meet bid price rule

CNS Pharmaceuticals, Inc.

Company received Nasdaq deficiency notice on Sept 12, 2024 for bid price below $1.00 for 30 consecutive days.
Not eligible for standard 180-day compliance period due to cumulative reverse stock splits of 250:1 or more in prior two years.
After hearing, Nasdaq panel granted exception until March 11, 2025 to regain compliance.
Panel reserves right to reconsider; Listing Council may review within 45 days.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.